Duodenal mucosa resurfacing: the endoscopic silver bullet against metabolic disorders?

Abstract

With the backset of the epidemic surge of type 2 diabetes (T2D), obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD), the key role of jejunal mucosa in the development of metabolic disorders, beyond its normal function in nutrient absorption, has become increasingly appreciated. In humans, compared to non-diabetic controls, diabetic patients have jejunal mucosa hypertrophy, hyperplasia of enteroendocrine cells, and increased numbers of enteroendocrine cells and enterocytes. Moreover, functional changes have also been observed, including variations in glucose transporters, enteric nerves, and intestinal microbiota composition. Duodenal mucosa resurfacing (DMR) starts with the assumption that resurfacing the mucosal interface will reset and correct any abnormal signaling from the duodenal mucosa and will, therefore, result in improved pancreatic endocrine function and glucose tolerance owing to restored normal mucosal surface. The endoscopic technique of DMR involves the hydrothermal ablation of the more superficial duodenal mucosal layers. Data reviewed indicate that DMR is a safe and well-tolerated procedure, with favorable outcomes on glucose homeostasis among those with T2D, body weight among those with obesity, and liver tests among those with MASLD. Additional studies are therefore urgently needed to ascertain, among the various surgical, endoscopic and medical choices, the best precision medicine option to fit the individual patient with T2D, obesity, and MASLD.

Keywords

BMI / C-peptide / HbA1c / metabolic dysfunction-associated steatotic liver disease / obesity / type 2 diabetes

References

[1] Zhang H,Shapiro MD.Global burden of metabolic diseases, 1990-2021.Metabolism2024;160:155999

[2] Rui L.Energy metabolism in the liver. In: Terjung R, Editor. Comprehensive physiology. Wiley; 2011. pp. 177-97. PMCID:PMC4050641

[3] Karpińska M.Pancreas-its functions, disorders, and physiological impact on the mammals’ organism.Front Physiol2022;13:807632 PMCID:PMC9005876

[4] Silva PH, Mohebbi N. Kidney metabolism and acid-base control: back to the basics.Pflugers Arch2022;474:919-34 PMCID:PMC9338915

[5] Petersen MC.Mechanisms of insulin action and insulin resistance.Physiol Rev2018;98:2133-223 PMCID:PMC6170977

[6] Pories WJ,MacDonald KG.Who would have thought it?.Ann Surg1995;222:339-50 PMCID:PMC1234815

[7] Hoyt JA,D’Alessio DA,Aroda VR.A look at duodenal mucosal resurfacing: rationale for targeting the duodenum in type 2 diabetes.Diabetes Obes Metab2024;26:2017-28

[8] Rønnestad I,Kaji I.Duodenal luminal nutrient sensing.Curr Opin Pharmacol2014;19:67-75 PMCID:PMC4845631

[9] Cherrington AD,Maggs D.Hydrothermal duodenal mucosal resurfacing: role in the treatment of metabolic disease.Gastrointest Endosc Clin N Am2017;27:299-311

[10] Rajagopalan H,Thompson CC.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study.Diabetes Care2016;39:2254-61

[11] Weiskirchen R.How ‘miracle’ weight-loss semaglutide promises to change medicine but can we afford the expense?.Br J Pharmacol2025;182:1651-70

[12] Lim GE.Glucagon-like peptide 1 secretion by the L-cell: the view from within.Diabetes2006;55:S70-7

[13] Holst JJ.The physiology of glucagon-like peptide 1.Physiol Rev2007;87:1409-39

[14] Mayo Clinic. Ablation therapy. Available from https://www.mayoclinic.org/tests-procedures/ablation-therapy/about/pac-20385072 [accessed 18 March 2025].

[15] West JA, Tsakmaki A, Huang JHS, et al. Proximal and distal gut mucosa adapt differently to westernized diet, promoting an insulin-resistant dysmetabolic state. bioRχiv 2019; bioRχiv:2019.

[16] Chiu HHC.Potential of duodenal mucosal resurfacing in achieving glycemic control in Asians with type 2 diabetes.Ther Adv Endocrinol Metab2024;15:20420188241252308 PMCID:PMC11075609

[17] Gong EJ.Small bowel endoscopic bariatric therapies.Clin Endosc2018;51:425-9 PMCID:PMC6182290

[18] Meiring S,van Baar ACG.Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events.Cardiovasc Diabetol2022;21:191 PMCID:PMC9503196

[19] Simons M.Updates in metabolic bariatric endoscopy.Dig Endosc2024;36:107-15

[20] van Baar ACG,Wong K.Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results.JHEP Rep2019;1:429-37 PMCID:PMC7005649

[21] van Baar ACG,Crenier L.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.Gut2020;69:295-303 PMCID:PMC6984054

[22] van Baar ACG,Smeele P.Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.Gastrointest Endosc2021;94:111-20.e3

[23] Hadefi A,Pezzullo M.Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study.Endosc Int Open2021;9:E1792-800 PMCID:PMC8589546

[24] van Baar ACG,Hopkins D.Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study).Diabetes Res Clin Pract2022;184:109194

[25] Meiring S,Sørensen N.A changed gut microbiota diversity is associated with metabolic improvements after duodenal mucosal resurfacing with glucagon-like-peptide-1 receptor agonist in type 2 diabetes in a pilot study.Front Clin Diabetes Healthc2022;3:856661 PMCID:PMC10012157

[26] Meiring S,van Baar ACG.Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.Am J Physiol Endocrinol Metab2022;322:E132-40 PMCID:PMC8858668

[27] Mingrone G, van Baar AC, Devière J, et al; Investigators of the REVITA-2 Study. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2022;71:254-64. PMCID:PMC8761999

[28] Chuang TJ,Shiu SI.The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease.Medicine2023;102:e35147 PMCID:PMC10553053

[29] Fonseca V,Saeed ZI.824-P: glycemic improvement, insulin reductions, and improved body weight 48 weeks after revita duodenal mucosal resurfacing in t2d patients with previously inadequately controlled glucose despite multiple glucose-lowering agents including insulin.Diabetes2023;72:824P.

[30] Busch CBE,van Baar ACG.Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot study.Gastrointest Endosc2024;100:473-80.e1

[31] Musso G,Saba F,Cassader M.Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: a systematic review.Med2024;5:75-58.e2

[32] Falcetta P,Citro F.De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.Acta Diabetol2023;60:53-60

[33] Nunes G,Coelho H.Prolonged fasting induces histological and ultrastructural changes in the intestinal mucosa that may reduce absorption and revert after enteral refeeding.Nutrients2023;16:128 PMCID:PMC10780540

[34] Aliluev A,Sterr M.Diet-induced alteration of intestinal stem cell function underlies obesity and prediabetes in mice.Nat Metab2021;3:1202-16 PMCID:PMC8458097

[35] Mussa BM,Verberne AJ.Implication of neurohormonal-coupled mechanisms of gastric emptying and pancreatic secretory function in diabetic gastroparesis.World J Gastroenterol2018;24:3821-33 PMCID:PMC6141338

[36] Müller TD,Bloom SR.Glucagon-like peptide 1 (GLP-1).Mol Metab2019;30:72-130 PMCID:PMC6812410

[37] Pillon NJ,Marshall SM.Metabolic consequences of obesity and type 2 diabetes: balancing genes and environment for personalized care.Cell2021;184:1530-44 PMCID:PMC9191863

[38] Telese A,Magee CG.Bariatric and metabolic endoscopy: a new paradigm.Clin Transl Gastroenterol2021;12:e00364 PMCID:PMC8216681

[39] Nie L,Zhang S,Zhou X.Duodenal mucosa: a new target for the treatment of type 2 diabetes.Endocr Pract2023;29:53-9

[40] Rajagopalan H,Klonoff DC.A gut-centric model of metabolic homeostasis.J Diabetes Sci Technol2022;16:1567-74 PMCID:PMC9631542

[41] Hadefi A,Huberty V.Metabolic endoscopy: today’s science-tomorrow’s treatment.United European Gastroenterol J2020;8:685-94 PMCID:PMC7437083

[42] Ghusn W,Abu Dayyeh BK.Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.Clin Endosc2024;57:701-10 PMCID:PMC11637673

[43] Matteo MV,Pontecorvi V.The evolution and current state of bariatric endoscopy in Western countries.Clin Endosc2024;57:711-24 PMCID:PMC11637666

[44] De Luca M,Eisenberg D.Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO/ASMBS).Surg Obes Relat Dis2024;20:991-1025

[45] Jastreboff AM, le Roux CW, Stefanski A, et al; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958-71.

[46] Nathan DM, Lachin JM, Bebu I, et al; GRADE Study Research Group. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med. 2022;387:1075-88. PMCID:PMC9832916

[47] Yang H.Duodenal mucosal resurfacing before its use in clinical practice.Gastrointest Endosc2022;96:875

[48] Cottam A,Roslin M.Exploring bariatric surgery’s impact on weight loss and diabetes: sodium and glucose receptor modulation.JSLS2024;28:e2023.00051 PMCID:PMC10984375

[49] Busch CBE,van Baar ACG,Nieuwdorp M.Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study.Gastrointest Endosc2024;100:896-904